Creative Medical Technology (NASDAQ:CELZ) Posts Quarterly Earnings Results, Meets Estimates

Creative Medical Technology (NASDAQ:CELZ) announced its quarterly earnings results on Friday. The company reported ($0.48) EPS for the quarter, meeting analysts’ consensus estimates of ($0.48), Zacks reports.

Creative Medical Technology Price Performance

Shares of Creative Medical Technology stock traded up $0.05 during trading hours on Friday, reaching $3.02. The company’s stock had a trading volume of 170,960 shares, compared to its average volume of 145,810. The stock has a market cap of $7.79 million, a P/E ratio of -1.04 and a beta of 2.05. The firm has a 50 day moving average price of $3.51 and a 200-day moving average price of $2.88. Creative Medical Technology has a one year low of $1.69 and a one year high of $6.90.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CELZ. Weiss Ratings reissued a “sell (d-)” rating on shares of Creative Medical Technology in a report on Wednesday. Wall Street Zen raised shares of Creative Medical Technology to a “sell” rating in a research report on Saturday, August 9th. Finally, Zacks Research raised Creative Medical Technology to a “hold” rating in a research report on Tuesday, August 12th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce”.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.